# Cytidine 5'-diphosphocholine (Citicoline)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cytidine-5-diphosphocholine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** CDP-choline, Cytidine diphosphate choline, Cytidine 5'-diphosphocholine, 5'-Cytidine diphosphocholine, Citicolina, CDP-Cholin, Cytidine-5'-diphosphocholine sodium, Somazina, Cognizin

## Overview

Citicoline (CDP-choline) is a naturally occurring nucleotide that serves as a precursor to phosphatidylcholine, a key structural phospholipid in neuronal membranes. It elevates brain choline and cytidine levels, supporting [acetylcholine](/ingredients/condition/cognitive) synthesis and [dopamine](/ingredients/condition/mood)rgic neurotransmission while promoting membrane repair and neuroprotection.

## Health Benefits

• May improve functional recovery in moderate to severe stroke patients - 33% vs 21% achieved full recovery in subgroup analysis (moderate evidence)
• Enhances cortical inhibitory mechanisms - significant improvement in short-interval intracortical inhibition via TMS measurement (preliminary evidence)
• Supports [cognitive function](/ingredients/condition/cognitive) post-stroke - improvements in Mini Mental Status Examination scores in dose-response trial (moderate evidence)
• Potentially benefits memory in healthy older adults - though specific trial details limited (preliminary evidence)
• Well-tolerated neuroprotective agent - similar adverse event profiles to placebo across multiple trials (strong evidence)

## Mechanism of Action

Citicoline is hydrolyzed in the gut and plasma into choline and cytidine, which cross the blood-brain barrier and are resynthesized intracellularly into CDP-choline via the Kennedy pathway, ultimately incorporating into phosphatidylcholine membranes. The choline moiety drives [acetylcholine](/ingredients/condition/cognitive) synthesis via choline acetyltransferase, while cytidine is converted to uridine, which upregulates [dopamine](/ingredients/condition/mood) D2 receptor density and enhances dopaminergic signaling. Additionally, citicoline inhibits phospholipase A2 activity and reduces arachidonic acid release, attenuating neuro[inflammatory](/ingredients/condition/inflammation) cascades following ischemic injury.

## Clinical Summary

A Cochrane-reviewed meta-analysis of randomized controlled trials in acute ischemic stroke patients found that citicoline (500–2000 mg/day) significantly increased the odds of full neurological recovery (33% vs. 21% in moderate-severity subgroups), though pooled results across all severities showed modest effect sizes. A double-blind RCT using transcranial magnetic stimulation (TMS) demonstrated significant improvement in short-interval intracortical inhibition (SICI), a biomarker of GABAergic cortical function, indicating enhanced inhibitory neurotransmission. Evidence for [cognitive enhancement](/ingredients/condition/cognitive) in healthy adults remains preliminary, with small sample sizes and heterogeneous outcome measures limiting generalizability. Overall, evidence is moderate for post-stroke recovery and preliminary for broader nootropic applications.

## Nutritional Profile

Citicoline (CDP-choline) is a nucleotide compound, not a traditional macronutrient source. It consists of cytidine and choline linked via a diphosphate bridge. As a supplement, it is not a meaningful source of calories, fat, carbohydrates, or protein. Key bioactive components per typical therapeutic dose (250–500 mg): Choline content approximately 18–21% by molecular weight (~45–105 mg choline per 250–500 mg dose), contributing to total daily choline intake (AI: 425–550 mg/day for adults). Cytidine content approximately 27–30% by molecular weight, which is converted endogenously to uridine — a pyrimidine nucleoside with neuroactive properties. Upon oral ingestion, citicoline is rapidly hydrolyzed in the intestinal lumen and liver into free choline and cytidine before systemic absorption; intact citicoline is not detected in plasma. Choline fraction is subsequently available for [acetylcholine](/ingredients/condition/cognitive) synthesis and phosphatidylcholine biosynthesis via the CDP-choline (Kennedy) pathway. Cytidine is converted to uridine in plasma, which crosses the blood-brain barrier and participates in neuronal membrane phospholipid synthesis. Bioavailability of oral citicoline is reported at approximately 90–100%, making it highly bioavailable relative to choline salts. No significant fiber, fat-soluble vitamins, minerals, or essential fatty acids are present.

## Dosage & Preparation

Clinically studied oral dosages range from 500mg to 2000mg daily, with 500mg identified as potentially optimal in stroke trials. Treatment is typically initiated within 24 hours of stroke onset and continued for 6 weeks. Recent trials have used 1000mg citicoline sodium salt (Rischiaril® Forte) for 8 weeks. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Citicoline is generally well tolerated at doses of 250–2000 mg/day, with the most commonly reported adverse effects being mild gastrointestinal disturbances, headache, and [insomnia](/ingredients/condition/sleep) at higher doses. It may theoretically potentiate cholinergic drugs such as [acetylcholine](/ingredients/condition/cognitive)sterase inhibitors (e.g., donepezil, rivastigmine), increasing the risk of cholinergic excess including nausea and bradycardia. Citicoline may partially antagonize the effects of levodopa due to enhanced [dopamine](/ingredients/condition/mood)rgic tone, and co-administration in Parkinson's patients should be supervised by a clinician. Safety data in pregnancy and lactation are insufficient, and use is not recommended in these populations without medical guidance.

## Scientific Research

Clinical evidence includes a 259-patient dose-response trial across 21 US centers showing significant improvements in functional and [cognitive](/ingredients/condition/cognitive) outcomes with 500-2000mg doses, and a 394-patient trial from 33 centers revealing benefits specifically in moderate to severe stroke patients (NIHSS ≥8). A recent pilot trial of 30 participants demonstrated neurophysiological improvements measured by TMS despite no clinical score changes.

## Historical & Cultural Context

The research provides no information about traditional or historical use of citicoline. It appears to be a modern pharmaceutical compound developed specifically for clinical neuroprotection rather than a traditional medicine.

## Synergistic Combinations

Phosphatidylcholine, Alpha-GPC, DHA omega-3, Phosphatidylserine, B-complex vitamins

## Frequently Asked Questions

### What is the recommended dosage of citicoline for cognitive support?

Clinical trials typically use 250–2000 mg/day of citicoline, with most cognitive benefit studies using 500–1000 mg/day divided into two doses. A 28-day RCT in healthy adults found 250 mg and 500 mg daily improved attention and psychomotor speed, suggesting lower doses may be effective for general cognitive use. Doses above 2000 mg/day have not demonstrated additional benefit and may increase the risk of gastrointestinal side effects.

### How long does it take for citicoline to work?

Measurable changes in brain phosphatidylcholine levels via phosphorus MRS have been observed within 4–6 weeks of supplementation at 500–2000 mg/day. Cognitive outcomes in clinical trials, such as improvements in memory and attention, are typically reported after 4–12 weeks of consistent use. Neurological improvements in stroke recovery settings have been assessed at 90 days post-event, reflecting the time required for axonal repair and membrane remodeling.

### Is citicoline the same as CDP-choline or alpha-GPC?

Citicoline and CDP-choline are the same compound — citicoline is the INN (International Nonproprietary Name) for cytidine 5'-diphosphocholine. Alpha-GPC (alpha-glycerophosphocholine) is a distinct choline-containing compound that delivers choline more directly without the cytidine component. Citicoline provides both choline (for acetylcholine and phospholipid synthesis) and cytidine (converted to uridine, which supports membrane repair and dopaminergic function), giving it a broader mechanistic profile than alpha-GPC.

### Can citicoline help with stroke recovery?

Multiple RCTs and a Cochrane meta-analysis support citicoline's role in functional recovery following ischemic stroke, particularly in moderate-severity cases, where 33% of citicoline-treated patients achieved full neurological recovery versus 21% of controls. The proposed mechanism involves inhibition of phospholipase A2, reduction of free radical generation, and acceleration of membrane phospholipid resynthesis in penumbral neurons. Benefit appears most pronounced when citicoline is administered within 24 hours of stroke onset at doses of 500–2000 mg/day, though evidence quality is rated moderate due to heterogeneity across trials.

### Does citicoline increase dopamine or acetylcholine?

Citicoline raises brain acetylcholine levels by providing choline as a substrate for choline acetyltransferase-mediated synthesis, an effect documented in animal models and supported by human neuroimaging data showing increased choline metabolite peaks. It also enhances dopaminergic neurotransmission by increasing uridine availability, which upregulates striatal dopamine D2 receptor density and potentiates dopamine release — an effect observed in PET imaging studies. These dual mechanisms make citicoline relevant to conditions involving both cholinergic deficit (e.g., Alzheimer's disease) and dopaminergic dysregulation (e.g., attention and motivation deficits).

### Is citicoline safe to take long-term?

Citicoline has demonstrated a favorable safety profile in clinical studies lasting several months to over a year, with minimal adverse effects reported at standard doses (500–2000 mg daily). Long-term use appears well-tolerated in both acute stroke recovery and chronic cognitive support applications. However, individual tolerance may vary, and consulting a healthcare provider before extended supplementation is advisable, particularly if you have existing neurological conditions.

### Does citicoline interact with blood pressure or stroke medications?

Citicoline is generally compatible with common stroke and cardiovascular medications, though it may have mild additive effects on blood pressure regulation. No major contraindications have been identified with antihypertensives, anticoagulants, or antiplatelet agents in clinical research. If you are taking prescription medications for hypertension or stroke prevention, inform your healthcare provider before adding citicoline to ensure safe concurrent use.

### What is the evidence strength for citicoline's cognitive benefits compared to its stroke recovery benefits?

Citicoline shows moderate to strong evidence for functional recovery in stroke patients, with studies demonstrating measurable improvements in neurological outcomes and cognition post-stroke. Evidence for cognitive enhancement in non-stroke populations is more limited and preliminary, suggesting it may be most beneficial as a neuroprotective agent following acute brain injury rather than for general cognitive optimization. The strongest clinical data supports its use in acute and subacute stroke settings rather than in healthy individuals seeking cognitive enhancement.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*